A detailed history of Telos Capital Management, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Telos Capital Management, Inc. holds 342 shares of REGN stock, worth $358,043. This represents 0.04% of its overall portfolio holdings.

Number of Shares
342
Previous 343 0.29%
Holding current value
$358,043
Previous $330,000 8.79%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$883.2 - $1071.19 $883 - $1,071
-1 Reduced 0.29%
342 $359,000
Q1 2024

Apr 24, 2024

SELL
$902.69 - $993.35 $902 - $993
-1 Reduced 0.29%
343 $330,000
Q4 2023

Jan 30, 2024

SELL
$775.18 - $881.7 $8,526 - $9,698
-11 Reduced 3.1%
344 $302,000
Q3 2023

Nov 01, 2023

SELL
$692.45 - $844.37 $11,771 - $14,354
-17 Reduced 4.57%
355 $292,000
Q2 2023

Jul 20, 2023

SELL
$700.03 - $830.35 $4,900 - $5,812
-7 Reduced 1.85%
372 $267,000
Q1 2023

Apr 27, 2023

SELL
$680.49 - $826.97 $27,900 - $33,905
-41 Reduced 9.76%
379 $311,000
Q4 2022

Jan 27, 2023

BUY
$705.89 - $766.39 $67,765 - $73,573
96 Added 29.63%
420 $0
Q3 2022

Oct 31, 2022

BUY
$573.97 - $724.32 $185,966 - $234,679
324 New
324 $223,000
Q2 2022

Aug 08, 2022

SELL
$548.35 - $738.84 $182,600 - $246,033
-333 Closed
0 $0
Q1 2022

May 02, 2022

BUY
$595.12 - $698.43 $1,785 - $2,095
3 Added 0.91%
333 $233,000
Q4 2021

Jan 21, 2022

SELL
$543.48 - $670.97 $1,086 - $1,341
-2 Reduced 0.6%
330 $208,000
Q3 2021

Oct 19, 2021

BUY
$574.03 - $680.96 $190,577 - $226,078
332 New
332 $201,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $112B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Telos Capital Management, Inc. Portfolio

Follow Telos Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Telos Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Telos Capital Management, Inc. with notifications on news.